WO2026003253A1 - Effets bénéfiques pour le soin de la peau obtenus à partir de compositions cosmétiques - Google Patents

Effets bénéfiques pour le soin de la peau obtenus à partir de compositions cosmétiques

Info

Publication number
WO2026003253A1
WO2026003253A1 PCT/EP2025/068224 EP2025068224W WO2026003253A1 WO 2026003253 A1 WO2026003253 A1 WO 2026003253A1 EP 2025068224 W EP2025068224 W EP 2025068224W WO 2026003253 A1 WO2026003253 A1 WO 2026003253A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
lactic acid
therapeutic use
skin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/068224
Other languages
English (en)
Inventor
Lynda Grainger
Anne-Sophie PIGGOTT
Linda Jane Wainwright
Emma Jayne Whitehead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Original Assignee
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Global IP Ltd, Unilever IP Holdings BV, Conopco Inc filed Critical Unilever Global IP Ltd
Publication of WO2026003253A1 publication Critical patent/WO2026003253A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A61K8/0229—Sticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/28—Zirconium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the invention is concerned with the use of cosmetic compositions and components thereof for giving skin care benefits; in particular, it is concerned with boosting the natural level of hyaluronic acid (HA) present within the skin.
  • HA hyaluronic acid
  • HA hyaluronic acid
  • HA may be formulated into a wide range of cosmetic skin care compositions and has been claimed to give numerous skin care benefits.
  • EP 2,347,755 B1 discloses cosmetic compositions comprising HA and other active ingredients for reducing skin wrinkles and/or the reduction of the depth of skin pores.
  • WO 2023/018959 discloses anhydrous cosmetic compositions comprising HA for use in improving skin qualities, in particular hydration.
  • the present invention is concerned with the use of lactic acid and salts thereof for increasing the natural level of HA within the skin, i.e., without the need for topical application of HA itself.
  • the present invention is particularly concerned with the use of lactic acid and its salts for the above purpose when applied from a deodorant or antiperspirant composition.
  • Lactic acid and its salts have been used in a wide range of cosmetic compositions, including deodorant and antiperspirant compositions.
  • JP 1040542 A2 discloses clear gel compositions comprising lactic acid salt, e.g. potassium lactate.
  • Mintel GNPD record ID 7109939 discloses Dove Talc Touch antiperspirant roll-on composition (Unilever, 2019) comprising potassium lactate.
  • Physical stress to the skin may be caused by abrasive treatments, in particular shaving, which commonly causes redness or soreness.
  • Another cause of physical stress is chafing, when the skins rubs against itself or clothing. Skin-to-skin chafing may occur in the underarms or in other areas of the body, such as the inner thighs or buttocks.
  • the invention may be of particular value when the composition is suitable for application to the whole body; for example, a whole body deodorant or antiperspirant.
  • Chemical stress to the skin may be caused by irritant chemical application, including the application of surfactants, in particular anionic surfactants.
  • surfactants in particular anionic surfactants.
  • Other ingredients that can lead to chemical stress include allergens and sensitisers.
  • lactic acid for boosting hyaluronic acid levels in the human skin, wherein the lactic acid or salt thereof is applied from a water-in-oil emulsion composition.
  • lactic acid or salt thereof for boosting hyaluronic acid levels in the human skin, wherein the lactic or salt thereof is applied from an aqueous polyol mixture.
  • lactic acid or salt thereof for boosting hyaluronic acid levels in the human skin, wherein the lactic acid or salt thereof is applied from an oil-in-water emulsion composition.
  • lactic acid or salt thereof for boosting hyaluronic acid levels in the human skin and for deodorising human skin.
  • boosting hyaluronic acid levels and deodorising human skin may be achieved in accordance with invention without the use of an additional deodorant active.
  • ambient conditions refer to 20°C and 1 atmosphere pressure, unless otherwise indicated.
  • water insoluble refers to materials having a solubility in water of less than 0.1 g/100g, under ambient conditions.
  • references to amounts of components such as “deodorant active” or “rheological modifier” relate to the total amount of such components present in the composition.
  • references to the dermis refer in particular to the papillary dermis, the top level of the dermis located immediately below the epidermis.
  • the lactic acid or a salt thereof used in the present invention serves as a skin care active.
  • compositions used in conjunction with the invention exclude, i.e. are free from, HA.
  • compositions used in the present invention is a cosmetically acceptable carrier.
  • a cosmetically acceptable carrier may be selected from any of those known in the art.
  • the cosmetically acceptable carrier comprises a carrier oil, i.e. a water insoluble substance which is liquid under ambient conditions.
  • the total amount of lactic acid and salts thereof is preferably at least 0.1 , more preferably at least 0.5% and most preferably at least 1%.
  • the lactic acid and salts thereof is preferably 20% or less, more preferably 12% or less and most preferably 6% or less. Preferred ranges may be formed from any of the lower and upper incorporation preferences indicated in this paragraph; e.g., from 0.5 to 20%.
  • Water is a preferred carrier in compositions used in the present invention.
  • the lactic acid is applied from an aqueous composition in preferred embodiments of the invention.
  • an aqueous composition is to be understood as a composition comprising water.
  • Aqueous compositions used in the invention have a preferred water content of at least 10%, more preferably at least 15% and most preferably at least 20%.
  • the lactic acid or salt thereof is topically applied. This is typically done from a cosmetic composition also comprising a cosmetically acceptable carrier. In preferred embodiments, the lactic acid or salt thereof is topically applied from a leave on cosmetic composition, such as an antiperspirant or deodorant composition.
  • the composition used is in the form of an emulsion, which may be a water-in-oil emulsion or an oil-in-water emulsion.
  • Water-in-oil emulsions are preferred when the composition is in the form of a stick, solidified with a structuring agent.
  • Oil-in-water emulsions are preferred when the composition is in the form of roll-on, lotion, or cream.
  • a cosmetic composition comprising lactic acid or salt thereof in a water-in-oil emulsion is used for boosting hyaluronic acid levels in the human skin.
  • Such compositions are preferably solidified with a structuring agent to give an emulsion stick, typically an opaque emulsion stick (OES).
  • OES opaque emulsion stick
  • solidified refers to a state of matter incapable of flow at a temperature of 25°C and a pressure of 1 atmosphere.
  • the structuring agent employed in emulsion sticks used in accordance with the invention may be a single structurant or a mixture of structurants.
  • the amount of the structuring agent used is preferably from 5%, more preferably from 7% and most preferably from 8%.
  • the upper amount is preferably up to 25%, more preferably up to 20% and most preferably up to 15%.
  • the preferred ranges of solidifying agent may be selected from any of the lower and upper amounts indicated in this paragraph.
  • the structuring agent mentioned immediately above is preferably a wax. More preferably the structuring agent is a polyolefin wax, in particular a polyethylene wax.
  • Such waxes are typically synthetic waxes, i.e. waxes synthesised from olefins in the case of polyolefin waxes and waxes synthesised from ethylene in the case of polyethylene waxes.
  • the aqueous phase of water-in-oil emulsions used in accordance with the invention typically comprises from 30 to 68% of the total composition. Preferably, it comprises from 40 to 65% and more preferably from 45 to 60% of the total composition.
  • the aqueous phase typically includes the lactic acid or salt thereof.
  • a preferred additional component of compositions used in the invention is an antiperspirant active. Such an active is preferably an astringent aluminium salt or aluminium-zirconium salt. Such salts are typically dissolved in an aqueous disperse phase of an emulsion and are commonly present in emulsion sticks used in accordance with the invention.
  • lactic acid or a salt thereof to boost HA levels in the skin when applied from an antiperspirant composition is particularly innovative. This is particularly true when an antiperspirant active comprising aluminium is included in the composition, as is the case with most commercial antiperspirant compositions.
  • a preferred antiperspirant active is aluminium sesquichlorohydrate (ASCH).
  • ASCH has the chemical formula of AI2OH4.4CI1.6 to AI2OH4.9CI1.1.
  • Most commercial ASCH samples are of chemical formula AI2OH4.7CI1.3 to AI2OH4.9CI1.1 and it is particularly preferred to use actives of this formula.
  • Particularly preferred AP actives comprise calcium and particularly preferred actives also comprise an amino acid, in particular glycine. Such actives are described in WO 2014/187685 (Unilever, 2014).
  • the calcium is typically added in the form of calcium chloride. It is especially preferred that such actives are calcium-activated ASCH salts.
  • AP actives that are complexes with glycine are preferred, particularly when they also comprise calcium and/or are activated by calcium.
  • a calcium-activated ASCH glycine complex is used.
  • the proportion of antiperspirant salt is calculated excluding the weight of any water of hydration but including any complexing agent that may be present, such as glycine and any activating agent, such as calcium chloride.
  • the weight concentration of the antiperspirant salt in the aqueous phase is commonly not higher than 50% and is advantageously at least 10%. In preferred embodiments its weight concentration is from 15 to 40% and in more preferred embodiments it is from 20 to 30%.
  • the weight of antiperspirant salt in the entire composition is usually at least 6% and is commonly up to 30%.
  • the range of antiperspirant salt concentration for the composition is preferably from 8% to 25% and more preferably from 10 to 20%.
  • a preferred additional component of the aqueous phase of water-in-oil emulsions used in accordance with the invention is glycerol.
  • the amount of glycerol is preferably from 1 to 25%, more preferably from 5 to 22% and most preferably from 10 to 20%. These preferred ratios aid with the sensory properties of the product.
  • the compositions are preferably homogeneous and/or single phase compositions. They preferably comprise propylene glycol (PG) and/or dipropyleneglycol (DPG) and a structuring agent to give a solid stick composition. More preferably they comprise PG, DPG, water and a structuring agent.
  • PG propylene glycol
  • DPG dipropyleneglycol
  • a structuring agent to give a solid stick composition. More preferably they comprise PG, DPG, water and a structuring agent.
  • the structuring agent that may be employed for the purpose indicated in the paragraph immediately above may be a single structurant or a mixture of structurants.
  • the structurant is present at from 0.5 to 15%, more preferably 1 to 10 wt.% and most preferably from 2 to 8%.
  • the structuring agent mentioned immediately above is preferably a C12 to C24 fatty acid or salt thereof. More preferably the structuring agent is a C16 to C18 fatty acid and most preferably it is sodium stearate.
  • the ratio of DPG to PG is preferably greater than 5:1. More preferably from 5.5:1 to 10:1 , even more preferably from 6:1 to 10:1 , and most preferably from 7:1 to 10:1.
  • the total level of DPG and PG is preferably from 30 to 70%, more preferably from 35 to 60% and most preferably from 40 to 50%.
  • DPG is preferably present at from 25 to 55%, more preferably from 30 to 50% and most preferably from 35 to 45%.
  • PG is preferably present at from 3 to 10%, more preferably from 4 to 8% and most preferably from 4.5 to 6.5%.
  • Each of the preference levels for DPG may be combined with each od the preference levels for PG. These amounts and ratios help with the sensory properties of the product and the deodorancy benefit that it delivers.
  • Aqueous compositions as used in accordance with the invention must comprise water.
  • water is present at from 18 to 40%, more preferably from 20 to 36% and most preferably from 22 to 30%.
  • the ratio of water to glycols is preferably from 20: 80 to 50: 50 and more preferably from 25: 75 to 45: 55. These amounts and ratios help to reduce or eliminate insoluble matter in stick compositions.
  • glycerol is a preferred additional component.
  • the ratio of dipropylene glycol to glycerol is preferably from 1 :1 to 3:1, more preferably from 1.5:1 to 2.75:1, and most preferably from 2:1 to 2.5:1.
  • the amount of glycerol is preferably from 1 to 25%, more preferably from 5 to 22% and most preferably from 10 to 20%. These preferred ratios aid with the sensory properties of the product.
  • an aqueous polyol mixture When used it is preferably a composition that is free of aluminium; in particular it is free of astringent aluminium salts that may serve as antiperspirant agents. In addition, it preferably has deodorising properties, i.e. it reduces the malodour on the surface of the human body following topical application.
  • a cosmetic composition comprising lactic acid or salt thereof in an oil-in-water emulsion is used for boosting hyaluronic acid levels in the human skin.
  • the composition is also used to deliver a deodorancy benefit and in particularly preferred embodiments, the composition is also used to deliver an antiperspirancy benefit.
  • the aqueous phase is typically the predominant phase, preferably comprising greater than 60%, more preferably greater than 75%, and most preferably greater than 80% by weight of the total composition.
  • a preferred additional component in compositions used in the invention is a humectant selected from glycerol and/or a PEG oligomer of weight average molecular weight of from 180 to 420.
  • Glycerol is an especially preferred humectant.
  • the humectant may enhance the skin care properties of the composition.
  • the humectant is present at a preferred level of from 1 to 25%, more preferably from 5 to 22% and most preferably from 10 to 20%, these levels being particularly relevant when the humectant is glycerol.
  • a preferred additional component in compositions used in the invention, and particularly in emulsion compositions, is a water soluble vitamin, such as Vitamin B3 or niacinamide.
  • a water soluble vitamin such as Vitamin B3 or niacinamide.
  • vitamins are present at a level at a preferred level of from 0.1 to 8%, more preferably from 0.5 to 6% and most preferably from 1 to 5% by weight of the total composition.
  • Such vitamins may enhance the skin care properties of the composition.
  • a preferred additional component in compositions used in the invention is a fragrance oil, alternatively known as a perfume oil.
  • the fragrance oil may comprise a single fragrance component or, more commonly, a plurality of fragrance components.
  • fragrance oils impart an odour, preferably a pleasant odour, to the composition.
  • the fragrance oil imparts a pleasant odour to the surface of the human body the composition is applied to the same.
  • the amount of fragrance oil in the composition is preferably up to 3%, advantageously is at least 0.5% and particularly preferably from 0.8% to 2%.
  • non-fragrance oils can improve the sensory properties of the composition on application and can lead to other benefits such as emolliency.
  • Preferred non-fragrance oils are alkyl ether oils having a boiling point of above 100°C and especially above 150°C, including polyalkyleneglycol alkyl ethers.
  • Such ethers desirably comprise between 10 and 20 ethylene glycol or propylene glycol units and the alkyl group commonly contains from 4 to 20 carbon atoms.
  • the preferred ether oils include polypropylene glycol alkyl ethers such as PPG-14-butylether and PPG-15-stearyl ether.
  • triglyceride oils commonly comprise the alkyl residues of aliphatic C?to Cis acids, the total number of carbon atoms being selected in conjunction with the extent of olefinic unsaturation and/or branching to enable the triglyceride to be liquid at 20°C.
  • the alkyl residues are linear Cis groups having one, two or three olefinic degrees of unsaturation, two or three being optionally conjugated, many of which are extractable from plants (or their synthetic analogues), including triglycerides of oleic acid, linoleic acid, conjugated linoleic acids, linolenic acid, petroselenic acid, ricinoleic acid, linolenelaidic acid, trans 7-octadecenoic acid, parinaric acid, pinolenic acid, punicic acid, petroselenic acid and stearidonic acid.
  • Suitable oils can include those derived from unsaturated Cis acids, including coriander seed oil, impatiens balsimina seed oil, parinarium laurinarium kernel fat oil, sabastiana brasilinensis seed oil, dehydrated castor seed oil, borage seed oil, evening primrose oil, aquilegia vulgaris oil, sunflower (seed) oil and safflower oil.
  • Other suitable oils are obtainable from hemp, and maize corn oil.
  • An especially preferred oil by virtue of its characteristics is sunflower (seed) oil.
  • suitable oils that can also be emollient oils, comprise alkyl or alkyl-aryl ester oils having a boiling point of above 150°C (and a melting point of below 20°C).
  • ester oils include oils containing one or two alkyl groups of 12 to 24 carbon atoms length, including isopropyl myristate, isopropyl palmitate and myristyl palmitate.
  • Other nonvolatile ester oils include alkyl or aryl benzoates such C12-15 alkyl benzoate, for example Finsolv TNTM or Finsolv SunTM.
  • Oil-in-water emulsion compositions used in accordance with the invention are preferably stabilised with a nonionic emulsifier system.
  • the nonionic emulsifier system comprises a low HLB ethoxylated alcohol (HLB less than 8) and a high HLB ethoxylated alcohol (HLB more than 12). More preferably, the low HLB ethoxylated alcohol has a HLB less than 5 and the high HLB ethoxylated alcohol has a HLB of more than 15.
  • the ratio of the low HLB ethoxylated alcohol to the high HLB ethoxylated alcohol is from 1 : 1 to 1 : 10 and more preferably from 2: 3 to 1 : 8.
  • the non-ionic emulsifier system preferably comprises from 0.5 to 10%, more preferably from 1 to 8%, and most preferably from 1 to 6%.
  • Oil-in-water emulsion compositions used in accordance with the invention are preferably thickened with a rheology modifier.
  • Preferred rheology modifiers are C16-C22 linear fatty alcohols and/or C16-C22 fatty acid glycerides. It is particular preferred to use both a C16-C22 linear fatty alcohol and a C16- C22 fatty acid glyceride.
  • a C16-C22 linear fatty alcohol is employed, it is preferably a C18 linear fatty alcohol and more preferable stearyl alcohol.
  • C16-C22 linear fatty alcohol is preferably used at from 1 to 12% of the total composition and more preferably at from 2 to 7% by weight of the total composition.
  • C16-C22 fatty acid glyceride is preferably rich in monoglyceride content, meaning that it comprises at least 25% C16-C22 fatty acid monoglyceride and more preferably at least 30% C16-C22 fatty acid monoglyceride.
  • C16-C22 glyceride preferably comprises at least 25% glyceryl monostearate and more preferably at least 30% of said monoglyceride.
  • C16-C22 fatty acid glyceride is preferably used at from 1 to 12% of the total composition and more preferably at from 2 to 7% by weight of the total composition.
  • a C16-C22 linear fatty alcohol and a C16-C22 fatty acid glyceride are employed, including combinations of the preferred and more preferred selections indicated above, there are certain preferred ratios between the two.
  • the ratio of the C16- C22 linear fatty alcohol to the C16-C22 fatty acid glyceride is preferably from 1: 4 to 4: 1, more preferably from 1 : 3 to 3: 1 and most preferably from 1: 2 to 2: 1, by weight.
  • the total content of the rheological modifier consisting of a C16-C22 linear fatty alcohol and/or a C16-C22 fatty acid glyceride is preferably from 4 to 20%, more preferably from 5 to 15% and most preferably from 6 to 13%, by weight of the total composition.
  • compositions used in the invention are typically shear-thinning, i.e. they are non-Newtonian fluids that decrease in viscosity as the shear rate is increased.
  • they At a shear rate of /10s, they have a viscosity of from 10,000 cPs to 300,000 cPs /s at 10 /s, measured at 20°C.
  • they Preferably, they have a viscosity of from 25,000 cPs to 300,000 cPs /s at 10 /s and more preferably a viscosity of from 50,000 cPs to 250,000 cPs /s at 10 /s, all measured at 20°C.
  • composition used in the invention include those described in the following paragraphs.
  • Wash-off agents may be included, often in an amount of up to 10%, to assist in the removal of the formulation from skin or clothing.
  • wash-off agents are typically nonionic surfactants such as esters or ethers containing a Cs to C22 alkyl moiety and a hydrophilic moiety comprising a polyoxyalkylene group (POE or POP).
  • POE polyoxyalkylene group
  • Skin-feel improvers e.g. talc or finely divided high molecular weight polyethylene
  • An optional component is a preservative system, such as sodium benzoate/citric acid and/or an antioxidant such BHT (butyl hydroxy toluene), each typically in an amount of from 0.01 to 0.5%.
  • a preservative system such as sodium benzoate/citric acid and/or an antioxidant such BHT (butyl hydroxy toluene), each typically in an amount of from 0.01 to 0.5%.
  • BHT butyl hydroxy toluene
  • the preparation of the Examples in Table 1 involved a preliminary step of ‘activating’ the ASCH with calcium chloride and glycine to give an “activated ASCH” (AASCH) solution.
  • AASCH activated ASCH
  • the ASCH, calcium chloride and glycine were heated together with the water for 2 hours at 87°C.
  • the final solution comprised 27.0% ACH, 3.4% calcium chloride and 2.6% glycine.
  • the emulsion stick compositions indicated in Table 1 were prepared by methods known in the art using the aqueous solution of AASCH prepared as described above.
  • the sticks were water-in-oil emulsions structured by the polyethylene wax. They had good deodorancy and antiperspirancy performance as a result of AASCH solution added to each. They differed only in the presence of potassium lactate in one and its replacement by water in the other. The Examples had good solidity and stability.
  • explants were treated topically with a paper disk soaked with a 1.25% w/w aqueous solution of sodium dodecyl sulphate (SDS), to induce irritation stress in the explants. Doing this increases the sensitivity of the explants to subsequent treatments. It also enables the subsequently applied treatments to be tested as to their ability to help skin recover from stress events.
  • the paper disks were removed after 24 hours of contact and the products to be tested were applied immediately afterwards. Products were applied topically at 2 l per 1 cm 2 explant (or ca. 2 mg/cm 2 ) and spread using a spatula.
  • the culture medium was half renewed (1 ml) on day 1 and fully renewed (2 ml) on day 2. Control explants did not receive any treatment except the culture medium renewal.
  • FFPE formal-fixed paraffin-embedded skin sections of the explants were prepared. These were sliced into 5 micron sections using a microtone. Hyaluronic acid immunostaining of the FFPE sections was performed with a biotinylated hyaluronic acid binding protein (HABP, Amsbio ref. AMS.HKD.BC41) diluted at 1:400 in PBS, BSA 0.3% for 1 hour at room temperature, with a biotin/streptavidin amplifying system and revealed by VIP (Vector laboratories, Ref. SK-4600), a substrate of peroxidase giving a violet stain once oxidised. The immunostaining was assessed by microscopical observation and semi-quantified by image analysis using the software cellSens (Olympus).
  • HABP biotinylated hyaluronic acid binding protein
  • HA levels refer to the percentage of the sample surface on which HA was found to be present.
  • Table 2 - Deo Stick Compositions Treatment with the 1.25% SLS solution reduced the hyaluronic acid level of the epidermis by 43% by day 3 of the study: from 22.1% coverage to 12.5% coverage.
  • the HA level was increased by 64% compared with the SLS treatment alone.
  • the HA level was increased by 48% compared with the SLS treatment alone. Both of these results were significant at the 99%; however, there was no significant difference between the two treatments.
  • the cosmetic cream compositions indicated in Table 3 were prepared by methods known in the art. They differed only in the presence of potassium lactate in one and its replacement by water in the other.
  • Table 3 Oil-in-Water Emulsion Compositions Treatment with the 1.25% SLS solution reduced the hyaluronic acid level of the epidermis by 84% by day 3 of the study: from 4.9% coverage to 0.8% coverage.
  • the HA level was increased by 22% compared with the SLS treatment alone, which was not a significant increase.
  • the explants were posttreated with P6 the HA level was increased by a massive 1828%, significant at the 95% level.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne l'utilisation non thérapeutique d'acide lactique, en particulier de l'acide lactique ou de son sel pour renforcer les taux d'acide hyaluronique dans la peau humaine.
PCT/EP2025/068224 2024-06-28 2025-06-27 Effets bénéfiques pour le soin de la peau obtenus à partir de compositions cosmétiques Pending WO2026003253A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24185294 2024-06-28
EP24185294.6 2024-06-28

Publications (1)

Publication Number Publication Date
WO2026003253A1 true WO2026003253A1 (fr) 2026-01-02

Family

ID=91737882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/068224 Pending WO2026003253A1 (fr) 2024-06-28 2025-06-27 Effets bénéfiques pour le soin de la peau obtenus à partir de compositions cosmétiques

Country Status (1)

Country Link
WO (1) WO2026003253A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285973A (en) * 1979-07-20 1981-08-25 Alberto-Culver Company Liquid composition for application to the skin
JPH1040542A (ja) 1996-07-19 1998-02-13 Fuji Photo Film Co Ltd 磁気記録媒体の製造方法
US20040043047A1 (en) * 1999-03-26 2004-03-04 Parfums Christian Dior Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of the CD44 membrane receptors of skin cells
US7090875B2 (en) * 2000-12-19 2006-08-15 Kabushiki Kaisha Yakult Honsha External skin preparations and process for producing the same
WO2014187685A1 (fr) 2013-05-20 2014-11-27 Unilever Plc Compositions antitranspirantes
EP2347755B1 (fr) 2009-03-20 2018-06-27 Evonik Schlüchtern GmbH Préparation cosmétique dotée d'un principe actif destiné à la réduction de plis et/ou à la réduction de la profondeur des pores cutanés
WO2020088905A1 (fr) * 2018-11-01 2020-05-07 Beiersdorf Ag Émulsion huile dans l'eau cosmétique comprenant de l'oxyde de zinc
WO2023018959A1 (fr) 2021-08-12 2023-02-16 Roc Opco Llc Composition d'acide hyaluronique et son utilisation seule et en combinaison avec des rétinoïdes pour améliorer la peau

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285973A (en) * 1979-07-20 1981-08-25 Alberto-Culver Company Liquid composition for application to the skin
JPH1040542A (ja) 1996-07-19 1998-02-13 Fuji Photo Film Co Ltd 磁気記録媒体の製造方法
US20040043047A1 (en) * 1999-03-26 2004-03-04 Parfums Christian Dior Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of the CD44 membrane receptors of skin cells
US7090875B2 (en) * 2000-12-19 2006-08-15 Kabushiki Kaisha Yakult Honsha External skin preparations and process for producing the same
EP2347755B1 (fr) 2009-03-20 2018-06-27 Evonik Schlüchtern GmbH Préparation cosmétique dotée d'un principe actif destiné à la réduction de plis et/ou à la réduction de la profondeur des pores cutanés
WO2014187685A1 (fr) 2013-05-20 2014-11-27 Unilever Plc Compositions antitranspirantes
WO2020088905A1 (fr) * 2018-11-01 2020-05-07 Beiersdorf Ag Émulsion huile dans l'eau cosmétique comprenant de l'oxyde de zinc
WO2023018959A1 (fr) 2021-08-12 2023-02-16 Roc Opco Llc Composition d'acide hyaluronique et son utilisation seule et en combinaison avec des rétinoïdes pour améliorer la peau

Similar Documents

Publication Publication Date Title
EP3538059B1 (fr) Compositions anti-transpirantes/déodorantes exempt d'aluminium
EP3534871B1 (fr) Compositions anti-transpirantes/déodorantes exempt d'aluminium
AU2017202102B2 (en) Antiperspirant compositions
US20160106649A1 (en) Antiperspirant compositions
JPH09506599A (ja) 消臭製剤
US9867765B2 (en) Antiperspirant compositions
TW200408398A (en) Chloasma amelioration composition and dullness amelioration composition
FR3012957A1 (fr) Compositions cosmetiques comprenant de l'acide spiculisporique et un ester d'acide gras et de (poly)glycerol, eventuellement polyoxyalkylene
EP3220878A1 (fr) Procédé de fabrication d'une composition anti-transpirante
WO2026003253A1 (fr) Effets bénéfiques pour le soin de la peau obtenus à partir de compositions cosmétiques
WO2026003274A1 (fr) Compositions cosmétiques bénéfiques pour les soins de la peau
WO2026003251A1 (fr) Bienfaits en matière de soin de la peau obtenus à partir de compositions cosmétiques
WO2026003311A1 (fr) Compositions cosmétiques en bâtonnet comprenant un actif anti-transpirant
WO2026002945A1 (fr) Effets bénéfiques pour la peau de compositions cosmétiques
AU2022308327B2 (en) Aqueous antiperspirant compositions
US20250152492A1 (en) Deodorant Compositions
WO2025103965A1 (fr) Compositions déodorantes en émulsion
JP2006169175A (ja) 液状油性化粧料
FR3148144A1 (fr) Composition biphasique et ses procédés
FR3163557A1 (fr) Composition cosmétique sous forme de micro- ou nano-émulsion riche en huile et son utilisation pour le nettoyage du corps humain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25736920

Country of ref document: EP

Kind code of ref document: A1